LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Rybelsus (semaglutide) is an oral GLP-1 receptor agonist used to manage type 2 diabetes, but its use requires careful consideration before surgery. This medication slows gastric emptying, which may influence anaesthetic safety in specific situations. Current UK guidance from the Centre for Perioperative Care (CPOC) and UK Clinical Pharmacy Association (UKCPA) emphasises individualised assessment rather than routine cessation. Most patients can continue Rybelsus for elective procedures, though withholding may be recommended during dose escalation, in the presence of gastrointestinal symptoms, or for certain higher-risk situations. Effective communication with your surgical and diabetes teams ensures safe perioperative management whilst maintaining glycaemic control.
Quick Answer: Most patients taking Rybelsus can continue the medication for elective surgery, though withholding may be recommended in specific higher-risk situations such as during dose escalation or when experiencing gastrointestinal symptoms.
Rybelsus (semaglutide) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycaemic control in adults with type 2 diabetes mellitus. Whilst highly effective for blood glucose management, this medication requires consideration in the perioperative period due to its effects on gastric emptying and metabolic function.
GLP-1 receptor agonists work by slowing gastric emptying, which helps regulate postprandial glucose levels during normal circumstances. This delayed gastric emptying may be a consideration before surgery, particularly for procedures requiring general anaesthesia. The risk of pulmonary aspiration — where stomach contents enter the lungs during anaesthesia — is primarily increased in specific situations, such as during the initial weeks of treatment or dose escalation, in patients experiencing active gastrointestinal symptoms, or those with known gastroparesis.
The medication's glucose-lowering effects must be balanced against the metabolic stress of surgery and fasting periods. Surgical procedures trigger a stress response that typically raises blood glucose levels. Importantly, GLP-1 receptor agonists like Rybelsus have a low risk of causing hypoglycaemia when used alone, though this risk increases when combined with insulin or sulphonylureas.
Anaesthetic safety is paramount, and current UK guidance from the Centre for Perioperative Care (CPOC) and UK Clinical Pharmacy Association (UKCPA) emphasises the importance of discussing GLP-1 agonist use with your surgical and anaesthetic teams. The approach to Rybelsus depends on multiple factors including the type of surgery, anaesthetic technique, your individual diabetes control, and whether you are experiencing any gastrointestinal symptoms. Your healthcare team will assess these factors to create a personalised perioperative plan that balances potential risks against glycaemic management.
The approach to Rybelsus before surgery should be individualised based on UK guidance and your specific circumstances. Rybelsus has a half-life of approximately one week, which influences perioperative planning.
For most elective surgical procedures, current UK guidance (CPOC and UKCPA) generally advises that oral semaglutide can be continued for most patients. However, your anaesthetist may recommend temporarily withholding Rybelsus in specific higher-risk situations, such as:
During the initial weeks of treatment or dose escalation
If you are experiencing active nausea, vomiting, or other gastrointestinal symptoms
If you have known gastroparesis or other risk factors for aspiration
For certain high-risk procedures, following local hospital policy
When withholding is recommended, this is typically on the day of surgery or according to your anaesthetist's individualised assessment, rather than a fixed timeframe for all patients.
For minor procedures under local anaesthesia where you remain fully conscious and your airway is not at risk, it is usually appropriate to continue Rybelsus. Similarly, many regional anaesthetic techniques (such as spinal or epidural anaesthesia) for procedures where you remain awake may not require medication cessation, though this decision should be made by your anaesthetist.
Emergency surgery presents a different scenario. When surgery is urgent, inform your anaesthetic team about your Rybelsus use, including when you last took a dose. Your anaesthetic team will implement appropriate safety measures based on their clinical assessment.
It is essential to inform your surgical team as soon as your operation is scheduled so they can provide specific guidance based on your procedure type, current dose, and individual circumstances. Never stop Rybelsus without medical advice, as this requires a plan for alternative glucose management.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
If your healthcare team recommends discontinuing Rybelsus before surgery, you will need a clear plan for maintaining glycaemic control during the perioperative period. The approach varies depending on your baseline diabetes control, other medications, and the duration of Rybelsus cessation required.
If you take Rybelsus as monotherapy (your only diabetes medication), your diabetes team may recommend:
Increased home blood glucose monitoring — checking levels at least four times daily (fasting and before meals) to identify any deterioration in control
Dietary modifications — maintaining a balanced, consistent carbohydrate intake whilst avoiding excessive simple sugars
Specialist input — in some cases, your diabetes team may recommend additional measures if your glucose control deteriorates significantly
For patients on combination therapy, your existing medications (such as metformin) will typically be continued with possible dose adjustments. Your diabetes team will provide specific guidance, as some medications also require modification around surgery — for example, SGLT2 inhibitors should be stopped at least 3 days before major surgery (4 days for ertugliflozin) due to diabetic ketoacidosis risk, and you should monitor blood ketones if unwell or if glucose exceeds 13 mmol/L. Metformin may be held on the day of surgery depending on renal function and procedure type.
Target glucose levels during this period should generally remain between 6–10 mmol/L for most patients (with 4–12 mmol/L being acceptable), though your individual targets may differ. Contact your diabetes team or GP urgently if:
Blood glucose consistently exceeds 15 mmol/L or persistently exceeds 20 mmol/L
Blood ketones are ≥1.5 mmol/L
You develop symptoms of hyperglycaemia (excessive thirst, frequent urination, fatigue)
You experience hypoglycaemia (blood glucose below 4 mmol/L)
For major surgery or if your diabetes control is suboptimal, a variable rate intravenous insulin infusion (VRIII) may be used during the perioperative period, following Joint British Diabetes Societies (JBDS) protocols. Your surgical pre-assessment team should review your glucose control and may arrange additional diabetes specialist input if needed before your operation proceeds.
Resuming Rybelsus following surgery requires careful consideration to ensure you can safely tolerate oral medications and maintain adequate nutrition. The decision depends on several factors including the type of surgery performed, your recovery progress, and gastrointestinal function.
General principles for restarting Rybelsus include:
Adequate oral intake — you should be eating and drinking normally, or near-normally, before reintroducing Rybelsus. The medication's effect on gastric emptying means it should not be restarted whilst you are experiencing nausea, vomiting, or significant gastrointestinal symptoms.
Stable clinical condition — any post-operative complications should be resolved or well-controlled. Acute illness, infection, or ongoing surgical issues may warrant delaying resumption.
Normal gastrointestinal function — particularly after abdominal or gastrointestinal surgery, your surgical team must confirm that bowel function has returned adequately.
Rather than following fixed timeframes, restart Rybelsus when you are tolerating oral intake without significant gastrointestinal symptoms, following your clinician's advice. If Rybelsus has been stopped for a prolonged period (several weeks), your diabetes team may recommend re-titration from a lower dose to minimise gastrointestinal side effects, similar to initial treatment.
After gastrointestinal surgery (such as bariatric procedures, bowel resection, or gastric surgery), absorption of oral medications may be affected. Your diabetes team will need to assess whether Rybelsus remains appropriate or whether alternative formulations (such as injectable semaglutide) or different medication classes should be considered.
If you required temporary insulin therapy during the perioperative period, this will typically be weaned as you restart Rybelsus and your glucose control stabilises. Never restart Rybelsus without confirmation from your medical team, and ensure you have clear written instructions regarding timing and any dose adjustments required. Contact your GP or diabetes team if you remain unable to tolerate oral medications beyond the expected recovery period.
If you experience any suspected side effects from Rybelsus, report them via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or via the Yellow Card app).
Effective communication between you, your surgical team, and your diabetes care providers is essential for safe perioperative management. Proactive discussion ensures all parties understand your medication regimen and can coordinate appropriate adjustments.
Key steps for optimal communication:
At the time of surgical booking:
Inform the booking team that you take Rybelsus for diabetes
Mention when you started Rybelsus and whether you are still in the dose escalation phase
Report any current gastrointestinal symptoms (nausea, vomiting, etc.)
Ask whether you will receive written guidance about managing medications
Request early pre-assessment if your surgery is complex or your diabetes control is suboptimal
During pre-operative assessment:
Bring a complete list of all medications including doses and timing
Mention your most recent HbA1c result if known (ideally <69 mmol/mol for elective surgery)
Discuss any previous difficulties with diabetes management during illness or fasting
Ask specific questions about Rybelsus management and whether you need additional monitoring
If fasting for more than one meal or if your control is suboptimal, ask whether a variable rate insulin infusion is planned
Clarify whether you need diabetes specialist review before surgery proceeds
Information to provide includes:
Duration of Rybelsus therapy, current dose, and any recent dose changes
Other diabetes medications
Frequency of hypoglycaemia or hyperglycaemia
Home monitoring routine and typical glucose ranges
Contact details for your diabetes team (GP, practice nurse, or hospital diabetes service)
If guidance seems unclear or contradictory, do not hesitate to seek clarification. Contact your GP or diabetes specialist nurse for advice, particularly if:
You have not received specific instructions about managing Rybelsus
Your surgery is scheduled within less than one week
You are unsure how to manage other diabetes medications
Your glucose control deteriorates after any medication changes
For emergency admissions, immediately inform the admitting team and anaesthetist about your Rybelsus use, including when you last took a dose. Modern perioperative care increasingly recognises the importance of GLP-1 agonist management, and your surgical team should have protocols in place. Patient safety depends on open dialogue — never assume your surgical team has complete information about your diabetes medications unless you have explicitly discussed them.
Most patients can continue Rybelsus for elective surgery, but your anaesthetist may recommend withholding it in specific situations such as during dose escalation, if you have gastrointestinal symptoms, or for certain higher-risk procedures. Always discuss your individual circumstances with your surgical team.
When withholding is recommended, this is typically on the day of surgery or according to your anaesthetist's individualised assessment, rather than a fixed timeframe. Rybelsus has a half-life of approximately one week, which your clinical team will consider when making recommendations.
Restart Rybelsus when you are tolerating oral intake without significant gastrointestinal symptoms and your clinical condition is stable, following your clinician's specific advice. After gastrointestinal surgery, your diabetes team will assess whether Rybelsus remains appropriate or if alternative treatments are needed.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
